Lei Chen, PhD presents Rarity SafeLock at The Global Engage Conference, London, December 7

Co-founder of Rarity Bioscience, Lei Chen, PhD presents Rarity SafeLock, our ultra sensitive targeted mutation detection approach that outperforms ddPCR sensitivity using flow cytometry readout. The presentation includes clinical data from AML patients including mutation-prone high-GC regions.

THE RESEARCH & TECHNOLOGY SERIES: qPCR & DIGITAL PCR / LIQUID BIOPSIES / FLOW CYTOMETRY

Not attending this event? Follow us on Linked in for more upcoming events or contact us directly

Abstracts

An ultra sensitive targed mutation detection approach using flow cytometry readout

The ability to observe, evaluate, and count even extremely rare nucleic acid sequence variants in biological samples is a frequent need in biology and medicine. In particular rare tumor-specific mutations in patient samples serve as excellent markers to monitor the course of malignant disease and response ot therapies in clinical routine, but improved assay techniques are needed for broad adoption. We describe herein a methodology – SafeLock assays – which provide for rapid and highly specific detection on rare DNA sequence variants. We demonstrate precise, ultra-sensitive detection of single-nucleotide mutant sequences from malignant cells against a 100,000-fold excess of DNA from normal cells in either bone marrow or peripheral blood, to follow the course of patients treated for acute myeloid leukemia (AML).

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »